Rituximab

Rituximab is a biologic medication that works by targeting a protein called CD20 on B-cells, which are a type of white blood cell. By binding to CD20, rituximab destroys these cells or helps the immune system destroy these cells, which can be helpful in treating certain conditions.

Nufactor carries the following rituximab brands:

Brand (Manufacturer)	FDA-Approved Indication(s) [abbreviated]
Riabni^® (Amgen, Inc.) www.riabni.com Rituxan^® (Genentech, Inc.) www.rituxan.com Ruxience^® (Pfizer Labs Division of Pfizer, Inc.) ruxience.pfizerpro.com Truxima^® (Celltrion, Inc.) www.truxima.com	Chronic Lymphocytic Leukemia (CLL) in combination with fludarabine and cyclophosphamide Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in combination with glucocorticoids Mature B-cell Non-Hodgkin’s Lymphoma (NHL) and mature B-cell acute leukemia (B-AL) in combination with chemotherapy Non-Hodgkin’s Lymphoma (NHL) alone or in combination with other agents Pemphigus Vulgaris (PV) Rheumatoid Arthritis (RA) in combination with methotrexate

Brand (Manufacturer)

FDA-Approved Indication(s) [abbreviated]

Riabni^® (Amgen, Inc.)
www.riabni.com
Rituxan^® (Genentech, Inc.)
www.rituxan.com
Ruxience^® (Pfizer Labs Division of Pfizer, Inc.)
ruxience.pfizerpro.com
Truxima^® (Celltrion, Inc.)
www.truxima.com

Chronic Lymphocytic Leukemia (CLL) in combination with fludarabine and cyclophosphamide
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in combination with glucocorticoids
Mature B-cell Non-Hodgkin’s Lymphoma (NHL) and mature B-cell acute leukemia (B-AL) in combination with chemotherapy
Non-Hodgkin’s Lymphoma (NHL) alone or in combination with other agents
Pemphigus Vulgaris (PV)
Rheumatoid Arthritis (RA) in combination with methotrexate

Last reviewed 01/15/2026

COVID 19 Pre-Visit Screen

•

Nursing Visit Guidance

Rituximab

Nufactor carries the following rituximab brands: